|Bid||18.02 x 3100|
|Ask||19.68 x 1300|
|Day's Range||18.30 - 19.69|
|52 Week Range||8.68 - 27.33|
|Beta (3Y Monthly)||2.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 1, 2017 - Feb 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.38|
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the Company will participate in fireside chat at the following healthcare conferences. Live audio webcast will be accessible from the Company’s website at https://immunomedics.com/investors/.
Immunomedics (IMMU) delivered earnings and revenue surprises of -25.00% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Morris Plains, New Jersey-based company said it had a loss of 34 cents. Losses, adjusted for non-recurring gains, were 35 cents per share. The results missed Wall Street expectations. ...
Strategic Manufacturing Partnership Entered into with Samsung BioLogics to Provide Anticipated Long-Term Supply of Sacituzumab Govitecan Commercial Launch Preparations Nearing.
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced its current clinical collaboration with AstraZeneca (AZN) and MedImmune for the development of Imfinzi® (durvalumab) and sacituzumab govitecan combination therapy has been broadened to include second-line metastatic non-small cell lung cancer (NSCLC). “Sacituzumab govitecan has shown very encouraging single-agent activity in NSCLC patients who have failed multiple lines of therapy.
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Wednesday, November 7, 2018 at 5:00 p.m. Eastern Time to discuss first quarter fiscal 2019 financial results and provide a corporate update. To access the conference call, please dial (877) 303-2523 or (253) 237-1755 using the Conference ID 1568527. The conference call will be webcast via the Investors page on the Company’s website at https://immunomedics.com/investors/.
NEW YORK, NY / ACCESSWIRE / October 22, 2018 / U.S. equities finished mostly lower on Friday as earlier gains due to upbeat corporate earnings were hamstrung by a weakness in housing sales. According to ...
NEW YORK, NY / ACCESSWIRE / October 18, 2018 / Major U.S. equities finished moderately lower on Wednesday with the Dow Jones dropping over 300 points after minutes from the Federal Reserve September’s ...
NEW YORK, Oct. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / October 12, 2018 / U.S. equities remained bearish on Thursday as worries over rising interest rate and sell-off in technology shares pressure major markets to lower. S&P 500 Index decreased 2.06 percent to close at 2,728.37 and the Nasdaq Composite Index closed down 1.25 percent to close at 7,329.06. The market losses are “a reaction from investors finally realizing we are in a higher interest-rate environment, and given the elevated level of stocks, market participants were likely looking for a reason to sell,” said Charlie Ripley, senior investment strategist for Allianz Investment Management.
Immunomedics, Inc., (IMMU) and Samsung BioLogics Co., Ltd. today announced the companies have entered into a long-term manufacturing partnership agreement under which Samsung will manufacture Immunomedics’ proprietary humanized antibody, hRS7, at its manufacturing facilities in Incheon, South Korea. “This agreement is an important part of our overall strategy to further enhance our supply chain and continue to improve our cost-structure,” said Dr. Morris Rosenberg, Chief Technology Officer of Immunomedics.
NEW YORK, NY / ACCESSWIRE / August 28, 2018 / U.S. markets rose Monday, with the S&P 500 and Nasdaq finishing at new records for the second consecutive session, on news of the new trade agreement with ...
Live audio webcast will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with institutional investors at these conferences.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks that hit 52-week highs Aug. 23.) Abbott Laboratories (NYSE: ABT ) Avanos Medical Inc ...
The Morris Plains, New Jersey-based company said it had a loss of 68 cents per share. Losses, adjusted for non-recurring costs, came to 34 cents per share. The results fell short of Wall Street expectations. ...
Biologics License Application Accepted for Filing and Granted Priority Review by the U.S. Commercial Launch Preparations on Track. Lifecycle Management Strategy Implemented to Advance Sacituzumab Govitecan ...
NEW YORK, NY / ACCESSWIRE / August 23, 2018 / Immunomedics, Inc. (NASDAQ: IMMU ) will be discussing their earnings results in their Q4 Earnings Call to be held on August 23, 2018 at 5:00 PM Eastern Time. ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 22) Acer Therapeutics Inc (NASDAQ: ACER ) Avanos Medical Inc (NYSE: ...